International Journal of Cancer Management

Published by: Kowsar

Myeloid Cell Leukemia-1 (MCL-1) siRNA Therapy Showed Cytotoxic Effect on T Cells Acute Lymphoblastic Leukemia

Shaghayegh Askarian-Amiri 1 , 2 , ** , Farzane Ordoni Aval 2 , Abbas Azadmehr 2 , * , Morteza Oladnabi 3 , 4 , Mahjoobeh Jafari Vesiehsari 5 and Mahmoud Hajiahmadi 6
Authors Information
1 Student Research Committee, Babol University of Medical Sciences, Babol, Iran
2 Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
3 Gorgan Congenital Malformations Research Center, Golestan University of Medical Sciences, Gorgan, Iran
4 Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
5 Genetic Department, Babol University of Medical Sciences, Babol, Iran
6 Department of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, Iran
Corresponding Authors:
Article information
  • International Journal of Cancer Management: April 30, 2019, 12 (4); e87773
  • Published Online: April 23, 2019
  • Article Type: Research Article
  • Received: December 17, 2018
  • Revised: March 12, 2019
  • Accepted: April 10, 2019
  • DOI: 10.5812/ijcm.87773

To Cite: Askarian-Amiri S, Ordoni Aval F , Azadmehr A, Oladnabi M, Jafari Vesiehsari M, et al. Myeloid Cell Leukemia-1 (MCL-1) siRNA Therapy Showed Cytotoxic Effect on T Cells Acute Lymphoblastic Leukemia, Int J Cancer Manag. 2019 ; 12(4):e87773. doi: 10.5812/ijcm.87773.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Mullighan CG. New strategies in acute lymphoblastic leukemia: Translating advances in genomics into clinical practice. Clin Cancer Res. 2011;17(3):396-400. doi: 10.1158/1078-0432.CCR-10-1203. [PubMed: 21149616].
  • 2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535-48. doi: 10.1056/NEJMra023001. [PubMed: 15071128].
  • 3. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program. 2009:353-61. doi: 10.1182/asheducation-2009.1.353. [PubMed: 20008221]. [PubMed Central: PMC2847371].
  • 4. Chiaretti S, Foa R. T-cell acute lymphoblastic leukemia. Haematologica. 2009;94(2):160-2. doi: 10.3324/haematol.2008.004150. [PubMed: 19181788]. [PubMed Central: PMC2635412].
  • 5. Bora RS, Gupta D, Mukkur TK, Saini KS. RNA interference therapeutics for cancer: Challenges and opportunities (review). Mol Med Rep. 2012;6(1):9-15. doi: 10.3892/mmr.2012.871. [PubMed: 22576734].
  • 6. Li Y, Ji P, Jin P. Probing the microRNA pathway with small molecules. Bioorg Med Chem. 2013;21(20):6119-23. doi: 10.1016/j.bmc.2013.05.030. [PubMed: 23791866]. [PubMed Central: PMC3789859].
  • 7. Timmons L, Court DL, Fire A. Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene. 2001;263(1-2):103-12. doi: 10.1016/S0378-1119(00)00579-5. [PubMed: 11223248].
  • 8. Lu ZJ, Mathews DH. Efficient siRNA selection using hybridization thermodynamics. Nucleic Acids Res. 2008;36(2):640-7. doi: 10.1093/nar/gkm920. [PubMed: 18073195]. [PubMed Central: PMC2241856].
  • 9. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW, et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene. 2011;30(16):1963-8. doi: 10.1038/onc.2010.559. [PubMed: 21132008].
  • 10. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA. 1993;90(8):3516-20. doi: 10.1073/pnas.90.8.3516. [PubMed: 7682708]. [PubMed Central: PMC46331].
  • 11. Placzek WJ, Wei J, Kitada S, Zhai D, Reed JC, Pellecchia M. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis. 2010;1. e40. doi: 10.1038/cddis.2010.18. [PubMed: 21364647]. [PubMed Central: PMC3032312].
  • 12. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 2009;66(8):1326-36. doi: 10.1007/s00018-008-8637-6. [PubMed: 19099185].
  • 13. Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol. 2009;187(3):429-42. doi: 10.1083/jcb.200904049. [PubMed: 19948485]. [PubMed Central: PMC2779245].
  • 14. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-78. doi: 10.1056/NEJMra052603. [PubMed: 16407512].
  • 15. Smits EL, Berneman ZN, Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: Current approaches. Oncologist. 2009;14(3):240-52. doi: 10.1634/theoncologist.2008-0165. [PubMed: 19289488].
  • 16. Xiao J, Yin S, Li Y, Xie S, Nie D, Ma L, et al. SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells. Acta Biochim Biophys Sin (Shanghai). 2009;41(8):699-708. doi: 10.1093/abbs/gmp058. [PubMed: 19657571].
  • 17. Szer J. The prevalent predicament of relapsed acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2012;2012:43-8. doi: 10.1182/asheducation-2012.1.43. [PubMed: 23233559].
  • 18. Fujita Y, Kuwano K, Ochiya T. Development of small RNA delivery systems for lung cancer therapy. Int J Mol Sci. 2015;16(3):5254-70. doi: 10.3390/ijms16035254. [PubMed: 25756380]. [PubMed Central: PMC4394474].
  • 19. Yang M, Mattes J. Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther. 2008;117(1):94-104. doi: 10.1016/j.pharmthera.2007.08.004. [PubMed: 17928059].
  • 20. Shan G. RNA interference as a gene knockdown technique. Int J Biochem Cell Biol. 2010;42(8):1243-51. doi: 10.1016/j.biocel.2009.04.023. [PubMed: 19442757].
  • 21. Devi GR. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 2006;13(9):819-29. doi: 10.1038/sj.cgt.7700931. [PubMed: 16424918].
  • 22. Ordoni Aval F, Askarian Amiri S, Azadmehr A, Oladnabi M, Saadat P, Ebrahimi H, et al. Gene silencing of TGFbetaRII can inhibit glioblastoma cell growth. Asian Pac J Cancer Prev. 2018;19(9):2681-6. doi: 10.22034/APJCP.2018.19.9.2681. [PubMed: 30256570]. [PubMed Central: PMC6249455].
  • 23. Karami H, Baradaran B, Esfahani A, Sakhinia M, Sakhinia E. Therapeutic effects of myeloid cell leukemia-1 siRNA on human acute myeloid leukemia cells. Adv Pharm Bull. 2014;4(3):243-8. doi: 10.5681/apb.2014.035. [PubMed: 24754007]. [PubMed Central: PMC3992959].
  • 24. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: Perspectives for new therapeutic interventions. Drug Resist Updat. 2002;5(2):65-72. doi: 10.1016/S1368-7646(02)00049-3. [PubMed: 12135582].
  • 25. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006;12(1):11-9. doi: 10.1158/1078-0432.CCR-04-1752. [PubMed: 16397018].
  • 26. Alotaibi MR, Hassan ZK, Al-Rejaie SS, Alshammari MA, Almutairi MM, Alhoshani AR, et al. Characterization of apoptosis in a breast cancer cell line after IL-10 silencing. Asian Pac J Cancer Prev. 2018;19(3):777-83. doi: 10.22034/APJCP.2018.19.3.777. [PubMed: 29582634]. [PubMed Central: PMC5980855].
  • 27. Warr MR, Shore GC. Unique biology of Mcl-1: Therapeutic opportunities in cancer. Curr Mol Med. 2008;8(2):138-47. doi: 10.2174/156652408783769580. [PubMed: 18336294].
  • 28. Sprick MR, Walczak H. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta. 2004;1644(2-3):125-32. doi: 10.1016/j.bbamcr.2003.11.002. [PubMed: 14996497].
  • 29. Juin P, Geneste O, Gautier F, Depil S, Campone M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer. 2013;13(7):455-65. doi: 10.1038/nrc3538. [PubMed: 23783119].
  • 30. Akagi H, Higuchi H, Sumimoto H, Igarashi T, Kabashima A, Mizuguchi H, et al. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer. 2013;16(1):100-10. doi: 10.1007/s10120-012-0153-6. [PubMed: 22527182].
  • 31. Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R, et al. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res. 2008;6(1):42-52. doi: 10.1158/1541-7786.MCR-07-0080. [PubMed: 18234961].
  • 32. Skoda C, Erovic BM, Wachek V, Vormittag L, Wrba F, Martinek H, et al. Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. Oncol Rep. 2008;19(6):1499-503. [PubMed: 18497956].
  • 33. Karami H, Baradaran B, Esfehani A, Sakhinia M, Sakhinia E. Down-regulation of Mcl-1 by small interference RNA induces apoptosis and sensitizes HL-60 leukemia cells to etoposide. Asian Pac J Cancer Prev. 2014;15(2):629-35. doi: 10.7314/APJCP.2014.15.2.629. [PubMed: 24568469].
  • 34. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: Down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res. 2007;13(7):2144-50. doi: 10.1158/1078-0432.CCR-06-2294. [PubMed: 17404098].
  • 35. Hao JH, Gu QL, Liu BY, Li JF, Chen XH, Ji YB, et al. Inhibition of the proliferation of human gastric cancer cells SGC-7901 in vitro and in vivo using Bcl-2 siRNA. Chin Med J (Engl). 2007;120(23):2105-11. doi: 10.1097/00029330-200712010-00008. [PubMed: 18167184].
  • 36. Meng WB, Liu JP, Wang XW, E LH. Effect of Bcl-2-siRNA on proliferation and apoptosis of pediatric acute B lymphoblastic leukemia (A-BLL) cells. Genet Mol Res. 2015;14(4):12427-36. doi: 10.4238/2015.October.16.9. [PubMed: 26505392].
  • 37. Liu HT, Lu CL. Effect of silencing Bcl-2 expression by small interfering RNA on radiosensitivity of gastric cancer BGC823 cells. Asian Pac J Trop Med. 2013;6(1):49-52. doi: 10.1016/S1995-7645(12)60199-0. [PubMed: 23317885].
  • 38. Gao J, Li L, Wu M, Liu M, Xie X, Guo J, et al. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One. 2013;8(6). e65138. doi: 10.1371/journal.pone.0065138. [PubMed: 23750239]. [PubMed Central: PMC3672200].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments